Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;91(3):359-65.
doi: 10.1007/s00277-011-1319-8. Epub 2011 Sep 21.

Is obesity a prognostic factor for acute myeloid leukemia outcome?

Hun Ju Lee  1 , Andrea S Licht, Andrew J Hyland, Laurie A Ford, Sheila N J Sait, Annemarie W Block, Maurice Barcos, Maria R Baer, Eunice S Wang, Meir Wetzler
Affiliations

Is obesity a prognostic factor for acute myeloid leukemia outcome?

Hun Ju Lee et al. Ann Hematol. 2012 Mar.

Abstract

Obesity adversely affects outcome in pediatric acute lymphocytic leukemia and acute myeloid leukemia (AML). We asked if obesity, measured by body mass index (BMI), affected outcome in 329 adult AML patients treated with high-dose cytarabine and idarubicin-containing regimens administered according to actual body weight. Age ≥ 60, unfavorable karyotype, secondary AML, and positive smoking status had adverse impact on overall survival in a multivariate analysis, while BMI did not. We conclude that high BMI should not be a barrier to administer high-dose cytarabine-containing regimens for AML induction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Curves based on Kaplan-Meier analyses assessing differences in overall survival by BMI status at diagnosis, excluding respondents who underwent allogeneic transplantation. Normal weight: n=97 (n=14 censored); Overweight: n=105 (n=18 censored); Obese: n=93 (n=19 censored). The + sign reflects censored patients. b Curves based on Kaplan-Meier analyses assessing differences in progression free survival by BMI status at diagnosis, excluding respondents who underwent allogeneic transplantation. Normal weight: n=57 (n=11 censored); Overweight: n=62 (n=15 censored); Obese: n=54 (n=17 censored). The + sign reflects censored patients
See this image and copyright information in PMC

References

    1. Calle EE, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638. - PubMed
    1. Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist. 2010;15 (10):1083–1101. - PMC - PubMed
    1. Hunter RJ, et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA) Cancer Treat Rev. 2009;35(1):69–78. - PubMed
    1. Sparreboom A, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25(30):4707–4713. - PubMed
    1. Lange BJ, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293(2):203–211. - PubMed

Publication types

MeSH terms